StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXFree Report) in a report released on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Up 0.7 %

NASDAQ:CPIX opened at $1.53 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.21 and a current ratio of 1.37. The company has a market capitalization of $21.71 million, a price-to-earnings ratio of -2.59 and a beta of 0.23. Cumberland Pharmaceuticals has a one year low of $1.38 and a one year high of $2.36. The stock has a 50-day simple moving average of $1.54 and a 200 day simple moving average of $1.78.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Free Report) last released its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.21% and a negative net margin of 21.67%. The firm had revenue of $8.50 million for the quarter.

Cumberland Pharmaceuticals Company Profile

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Recommended Stories

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.